Turmeric Acquisition ^{Priced, Nasdaq: TMPMU}

MPM Capital (“MPM”) is a healthcare investment firm with over two decades of experience founding and investing in life science companies that seek to translate scientific innovations into cures for major diseases. With its experienced and dedicated team of investment professionals and Executive Partners, MPM strives to power novel medical breakthroughs that transform patients’ lives. MPM retains a primary focus on investing in companies with preclinical technologies and financing them through human clinical proof-of-concept (“POC”). Our independent directors have extensive experience in clinical medicine, development and regulatory affairs, operations within academia as well as the healthcare and financial industry. All of our independent directors have led or been a part of leadership teams in biotechnology companies that have together generated billions in value for investors and helped develop numerous FDA approved drugs for patients. While we may pursue an initial business combination opportunity in any industry or geographical location, we intend to capitalize on the ability of our management team to identify promising opportunities in the biotechnology sector, with an emphasis on oncology and rare disease therapeutics where our management has extensive experience in investing, operating and drug development.